Zenas BioPharma, Inc. (ZBIO)
NASDAQ · Manufacturing · Pharmaceutical preparations
$26.95−$0.5500 (−2.00%) on the dayAs of the close; data may be delayed.
ZBIO price, last 12 months
Key stats
- Previous close
- $27.50
- Open
- $27.44
- Day range
- $25.90 – $28.50
- 52-week range
- $13.50 – $44.60
- Volume
- 674.1K
- Avg volume (20 days)
- 659.5K
- Market cap
- $1.8B
Performance
1W−14.4%
1M−18.4%
3M+4.2%
6M+21.6%
YTD−25.8%
1Y+32.9%
vs S&P 500, 1Y+16.1 pts
Technicals and fundamentals
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.8B